Greenland Mines Ltd (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company’s Biotech Division. The patent relates to the expression of the human Klotho protein for the treatment of neuromuscular diseases. This intellectual property strengthens the company's Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
The patent supports the development of Greenland Mines' KLTO-202 program, which targets amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness and loss of voluntary movement. The Klotho protein has been studied for its potential roles in aging and neuroprotection, and its expression via gene therapy could offer a novel approach to slowing or halting disease progression.
Greenland Mines operates through two divisions: Mining and Biotech. The Mining division focuses on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of a previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland. The Biotech division is advancing the KLTO-202 program for ALS. The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
This patent grant is significant for Greenland Mines as it secures key intellectual property rights in Australia, a major market for biotech innovation. For the biotechnology industry, the patent adds to the growing body of IP around Klotho-based therapies, potentially influencing research directions and collaborations. For patients and families affected by ALS, the advancement of the KLTO-202 program offers hope for new treatment options. The news also highlights the convergence of mining and biotech interests within the same company, which may attract investors interested in diversified exposure across critical materials and therapeutic developments.
For more information about Greenland Mines, visit the company’s newsroom at https://nnw.fm/GRML. The full press release can be accessed at https://nnw.fm/PVbbH.
